SageView Advisory Group’s Crinetics Pharmaceuticals CRNX Stock Holding History

SageView Advisory Group’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$5.12K	Buy	+110	New	+$4.9K	﹤0.01%	1962

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

SageView Advisory Group's CRNX Position: Q4 2025 in Review

SageView Advisory Group opened a new position in Crinetics Pharmaceuticals (CRNX) in Q4 2025: 110 shares worth $5.12K. The stake represents ﹤0.01% of the portfolio and ranks #1962 among its holdings.

240 funds tracked by Wall St. Rank hold CRNX as of Q4 2025.

SageView Advisory Group held 110 shares of Crinetics Pharmaceuticals worth $5.12K as of Q4 2025.
Crinetics Pharmaceuticals was a new SageView Advisory Group position in Q4 2025.
Crinetics Pharmaceuticals made up ﹤0.01% of SageView Advisory Group's portfolio in Q4 2025, its #1962 holding.
240 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q4 2025.

Based on SageView Advisory Group's 13F filing for Q4 2025, filed 17 Feb 2026.